-

01:15:05 PM

ALPMY Stock News

ALPMY - Astellas Pharma Inc.

09/20/23 9:00 AM

OTC : ALPMY

partnership

Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)

Iveric Bio, An Astellas Company, today announced a...

RHEA-AI

neutral

09/18/23 7:00 PM

OTC : ALPMY

clinical trial

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Astellas Pharma Inc. today announced positive 24- month topline results from the...

RHEA-AI

neutral

09/18/23 6:00 PM

OTC : ALPMY

Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize

Astellas Venture Management LLC, a wholly owned venture capital subsidiary of...

RHEA-AI

positive

09/18/23 8:02 AM

OTC : ALPMY

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society

Astellas Pharma Inc. will share new pooled efficacy and safety analyses from the pivotal Phase 3 SKYLIGHT™ studies for VEOZAH™, its first-in-class treatment for moderate to...

RHEA-AI

negative

09/14/23 2:00 AM

OTC : ALPMY

Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland

This investment by Astellas in Ireland will expand our capacity and capabilities for aseptic drug products, reinforce stable production for global supply and accelerate the development and commercialization of innovative antibody drugs and other new products. Michael Lohan, CEO at IDA* "This announcement from Astellas is excellent news for the South West...

RHEA-AI

neutral

09/12/23 7:30 PM

OTC, NYSE : ALPMY, PFE

European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. today announced that the European Medicines Agency has validated its Type II variation for XTANDI ® for the treatment of patients with non-metastatic...

RHEA-AI

neutral

08/23/23 6:45 AM

OTC, NYSE : ALPMY, PFE

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Pfizer Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the companies' supplemental New Drug Application for...

RHEA-AI

neutral

08/17/23 7:30 PM

OTC : ALPMY

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Astellas Pharma Inc., today announced the European Medicines Agency has accepted for regulatory review the marketing authorization application for avacincaptad pegol, an investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to age-related macular degeneration.

RHEA-AI

negative

08/09/23 7:30 PM

OTC : ALPMY

Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood

Astellas Pharma Inc. and DivcoWest, a DivCore Capital Company, announced today plans for Astellas to open a new state-of-the-art life sciences facility at 441 Morgan Avenue, in the Cambridge Crossing neighborhood in Cambridge, Mass. This investment establishes a significant presence for Astellas in one of the...

RHEA-AI

positive

08/07/23 9:00 AM

Nasdaq, OTC : PSTX, ALPMY

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Astellas Pharma Inc. and Poseida Therapeutics, Inc....

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next